{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:50:20Z","timestamp":1785891020434,"version":"3.56.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ard.2025.02.019","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T15:17:56Z","timestamp":1744384676000},"page":"979-991","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Efficacy and safety of izokibep in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study"],"prefix":"10.1016","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7766-6167","authenticated-orcid":false,"given":"Peter C.","family":"Taylor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-0457","authenticated-orcid":false,"given":"Philip J.","family":"Mease","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3848-5122","authenticated-orcid":false,"given":"Kurt","family":"de Vlam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shephard","family":"Mpofu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Wetzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5742-6844","authenticated-orcid":false,"given":"Anne M.","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Wiens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa Osterling","family":"Koskinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8258-1643","authenticated-orcid":false,"given":"Sven","family":"Ohlman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2043-2482","authenticated-orcid":false,"given":"Joachim","family":"Feldwisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6421-4142","authenticated-orcid":false,"given":"Fredrik Y.","family":"Frejd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolai C.","family":"Brun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Brandt-Juergens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edit","family":"Drescher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9363-145X","authenticated-orcid":false,"given":"Eva","family":"Dokoupilova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Rowi\u0144ska-Osuch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Abdel-Kader Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8750-7186","authenticated-orcid":false,"given":"Frank","family":"Behrens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.ard.2025.02.019_bib0001","first-page":"S22","article-title":"Outcome measures in psoriatic arthritis: where next?","volume":"20","author":"Hackett","year":"2022","journal-title":"Musculoskeletal Care"},{"key":"10.1016\/j.ard.2025.02.019_bib0002","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/j.1468-3083.2009.03463.x","article-title":"The risk of psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in European dermatology clinics","volume":"24","author":"Christophers","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ard.2025.02.019_bib0003","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1002\/acr.24820","article-title":"All-cause and cause-specific mortality in psoriatic arthritis and ankylosing spondylitis: a systematic review and meta-analysis","volume":"75","author":"Chaudhary","year":"2023","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.ard.2025.02.019_bib0004","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00296-020-04775-2","article-title":"Comorbidities in psoriatic arthritis: a systematic review and meta-analysis","volume":"41","author":"Gupta","year":"2021","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.ard.2025.02.019_bib0005","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1016\/S0140-6736(18)30830-4","article-title":"The pathogenesis of psoriatic arthritis","volume":"391","author":"Veale","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ard.2025.02.019_bib0006","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","article-title":"The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis","volume":"55","author":"Blauvelt","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.ard.2025.02.019_bib0007","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/s41584-019-0243-5","article-title":"Systemic effects of IL-17 in inflammatory arthritis","volume":"15","author":"Beringer","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.ard.2025.02.019_bib0008","first-page":"680","article-title":"The burden of psoriatic arthritis: a literature review from a global health systems perspective","volume":"35","author":"Lee","year":"2010","journal-title":"P T"},{"key":"10.1016\/j.ard.2025.02.019_bib0009","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","article-title":"Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF\u03b1 inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ard.2025.02.019_bib0010","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","article-title":"Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial","volume":"382","author":"McInnes","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ard.2025.02.019_bib0011","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.02.019_bib0012","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1136\/annrheumdis-2017-212687","article-title":"Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study","volume":"77","author":"Mease","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.02.019_bib0013","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0140-6736(22)02302-9","article-title":"Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)","volume":"401","author":"McInnes","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ard.2025.02.019_bib0014","doi-asserted-by":"crossref","first-page":"839","DOI":"10.3899\/jrheum.190677","article-title":"Prevalence of psoriatic arthritis patients achieving minimal disease activity in real-world studies and randomized clinical trials: systematic review with metaanalysis","volume":"47","author":"Zardin-Moraes","year":"2020","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ard.2025.02.019_bib0015","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1080\/14656566.2021.2006184","article-title":"Current unmet needs and emerging novel pharmacotherapies in psoriatic arthritis","volume":"23","author":"Tahir","year":"2022","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ard.2025.02.019_bib0016","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1007\/s10067-019-04446-z","article-title":"Unmet needs in psoriatic arthritis patients receiving immunomodulatory therapy: results from a large multinational real-world study","volume":"38","author":"Alten","year":"2019","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ard.2025.02.019_bib0017","article-title":"Real-life retention rates and reasons for switching of biological DMARDs in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis","volume":"8","author":"Bhushan","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ard.2025.02.019_bib0018","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/14712598.2024.2357381","article-title":"Switching patterns of biological drugs in patients with psoriasis and psoriatic arthritis: insight from the VALORE database network","volume":"24","author":"Spini","year":"2024","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.ard.2025.02.019_bib0019","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1093\/rheumatology\/keab784","article-title":"Efficacy and safety of secukinumab in patients with spondyloarthritis and enthesitis at the Achilles tendon: results from a phase 3b trial","volume":"61","author":"Behrens","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.02.019_bib0020","first-page":"433","article-title":"Management of nail disease in patients with psoriatic arthritis: an updated literature review informing the 2021 GRAPPA treatment recommendations","volume":"50","author":"Laheru","year":"2023","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ard.2025.02.019_bib0021","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2209920","article-title":"Izokibep: preclinical development and first-in-human study of a novel IL-17A neutralizing affibody molecule in patients with plaque psoriasis","volume":"15","author":"Klint","year":"2023","journal-title":"MAbs"},{"key":"10.1016\/j.ard.2025.02.019_bib0022","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/bjd\/ljad186","article-title":"Izokibep for the treatment of moderate-to-severe plaque psoriasis: a phase II, randomized, placebo-controlled, double-blind, dose-finding multicentre study including long-term treatment","volume":"189","author":"Gerdes","year":"2023","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ard.2025.02.019_bib0023","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis: development of new criteria from a large international study","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"Suppl 11","key":"10.1016\/j.ard.2025.02.019_bib0024","first-page":"S64","volume":"63","author":"Mease","year":"2011","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"10.1016\/j.ard.2025.02.019_bib0025","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.rdc.2016.01.002","article-title":"Patient-reported outcomes in psoriatic arthritis","volume":"42","author":"Orbai","year":"2016","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.ard.2025.02.019_bib0026","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/S0140-6736(17)31429-0","article-title":"Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial","volume":"389","author":"Nash","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ard.2025.02.019_bib0027","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3899\/jrheum.170429","article-title":"Efficacy and safety of ixekizumab in patients with active psoriatic arthritis: 52-week results from a phase III study (SPIRIT-P1)","volume":"45","author":"van der Heijde","year":"2018","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ard.2025.02.019_bib0028","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.ard.2025.02.019_bib0029","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3899\/jrheum.170449","article-title":"Minimal disease activity as a treatment target in psoriatic arthritis: a review of the literature","volume":"45","author":"Gossec","year":"2018","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ard.2025.02.019_bib0030","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ard.2025.02.019_bib0031","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0140-6736(22)02303-0","article-title":"Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-alpha inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)","volume":"401","author":"Merola","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ard.2025.02.019_bib0032","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1136\/annrheumdis-2019-216835","article-title":"Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials","volume":"80","author":"Mease","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.02.019_bib0033","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s40744-020-00242-3","article-title":"Impact of enthesitis on psoriatic arthritis patient-reported outcomes and physician satisfaction with treatment: data from a multinational patient and physician survey","volume":"7","author":"Orbai","year":"2020","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.ard.2025.02.019_bib0034","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-002074","article-title":"Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes","volume":"8","author":"McInnes","year":"2022","journal-title":"RMD Open"},{"key":"10.1016\/j.ard.2025.02.019_bib0035","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002366","article-title":"Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial","volume":"8","author":"Helliwell","year":"2022","journal-title":"RMD Open"},{"key":"10.1016\/j.ard.2025.02.019_bib0036","doi-asserted-by":"crossref","first-page":"4793","DOI":"10.4049\/jimmunol.170.9.4793","article-title":"Albumin-based drug delivery as novel therapeutic approach for rheumatoid arthritis","volume":"170","author":"Wunder","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.ard.2025.02.019_bib0037","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s12257-019-0512-9","article-title":"Albumin: an emerging opportunity in drug delivery","volume":"25","author":"Rahimizadeh","year":"2020","journal-title":"Biotechnol Bioprocess Eng"},{"key":"10.1016\/j.ard.2025.02.019_bib0038","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1136\/annrheumdis-2021-222027","article-title":"Safety of ixekizumab in patients with psoriatic arthritis: data from four clinical trials with over 2000 patient-years of exposure","volume":"81","author":"Deodhar","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.02.019_bib0039","first-page":"2958","article-title":"Efficacy and safety of IL-17 inhibitors for patients with psoriatic arthritis: a systematic review and meta-analysis","volume":"25","author":"Gao","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.ard.2025.02.019_bib0040","doi-asserted-by":"crossref","first-page":"adv00698","DOI":"10.2340\/actadv.v102.563","article-title":"Long-term safety of secukinumab over five years in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis and ankylosing spondylitis: update on integrated pooled clinical trial and post-marketing surveillance data","volume":"102","author":"Gottlieb","year":"2022","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.ard.2025.02.019_bib0041","article-title":"Risk of candidiasis associated with interleukin-17 inhibitors: a real-world observational study of multiple independent sources","volume":"13","author":"Davidson","year":"2022","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.ard.2025.02.019_bib0042","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/art.41923","article-title":"Risk of inflammatory bowel disease in patients with psoriasis and psoriatic arthritis\/ankylosing spondylitis initiating interleukin-17 inhibitors: a nationwide population-based study using the French National Health Data System","volume":"74","author":"Penso","year":"2022","journal-title":"Arthritis Rheumatol"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725008155?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725008155?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T05:11:31Z","timestamp":1774415491000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496725008155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0003496725008155"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2025.02.019","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of izokibep in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2025.02.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}